What it's for (Indications)
- Nimesulide, a non-steroidal anti-inflammatory drug (NSAID), is indicated for the short-term symptomatic treatment of acute pain and primary dysmenorrhea.
- It is also used for the symptomatic treatment of osteoarthritis, though its use is generally restricted to limited durations due to potential safety concerns.
- Its analgesic and anti-inflammatory properties render it effective in conditions requiring rapid relief from pain and inflammation.
- Due to its safety profile, particularly concerning hepatic effects, its prescribing is often reserved for situations where other NSAIDs are not suitable or have been found ineffective, and treatment duration should be kept to a minimum.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults, the typical recommended dose of nimesulide is 100 mg, taken twice daily, preferably after meals. The maximum daily dose should not exceed 200 mg. Due to its potential for serious adverse effects, particularly hepatotoxicity, treatment with nimesulide should be limited to the shortest possible duration necessary to control symptoms, usually not exceeding 15 consecutive days. Dosage adjustments may be necessary in elderly patients or those with mild to moderate renal impairment, and caution is advised. Nimesulide is generally not recommended for use in children under 12 years of age. Adherence to prescribed dosages and treatment duration is crucial to minimize risks. |
Safety & Warnings
Common Side Effects
- Common side effects associated with nimesulide include gastrointestinal disturbances such as nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.
- More serious but less frequent gastrointestinal effects can include gastric or duodenal ulcers, bleeding, and perforation.
- Hepatic adverse reactions are a significant concern, ranging from elevated liver enzymes to severe hepatitis, cholestasis, and fulminant hepatic failure.
- Other potential side effects include dizziness, somnolence, skin rash, pruritus, edema, hypertension, and renal impairment.
- In rare cases, severe hypersensitivity reactions (e.
- g.
- , anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis) and hematological disorders (e.
- g.
- , anemia, thrombocytopenia) have been reported.
- Patients should be advised to seek medical attention if they experience any severe or persistent side effects.
Serious Warnings
- Black Box Warning: Due to significant safety concerns, nimesulide carries a prominent warning regarding its potential for severe adverse events. **Hepatotoxicity:** Nimesulide has been associated with a significant risk of severe and potentially fatal hepatotoxicity, including fulminant hepatic failure requiring liver transplantation or leading to death. The risk of liver injury appears to be unpredictable and can occur at any time during treatment. Patients developing symptoms suggestive of liver injury (e.g., anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine, jaundice) must discontinue nimesulide immediately and seek urgent medical evaluation. **Cardiovascular Thrombotic Events:** Nimesulide, like other NSAIDs, may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors for such disease. **Gastrointestinal Risk:** NSAIDs, including nimesulide, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and those with a history of gastrointestinal disease are at greater risk for serious gastrointestinal events. Due to these serious risks, nimesulide's use is restricted in many countries and should only be considered for short-term treatment of acute pain and primary dysmenorrhea when other treatments are not suitable, and at the lowest effective dose for the shortest duration possible.
- Nimesulide carries significant warnings akin to other NSAIDs regarding cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
- These risks may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors.
- It also poses a serious risk of gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during therapy without warning symptoms and can be fatal.
- A prominent and unique warning for nimesulide pertains to severe hepatotoxicity, including fulminant hepatic failure, which has led to liver transplantation or death.
- Patients should be monitored for signs of liver injury.
- Other warnings include renal toxicity, hypertension, fluid retention, and hypersensitivity reactions.
- Nimesulide should be used with extreme caution in patients with a history of asthma or NSAID-induced allergic reactions.
How it Works (Mechanism of Action)
Nimesulide exerts its therapeutic effects primarily through selective inhibition of cyclooxygenase-2 (COX-2), an isoform of the cyclooxygenase enzyme responsible for the synthesis of pro-inflammatory prostaglandins. By selectively inhibiting COX-2, nimesulide reduces the production of these inflammatory mediators, thereby providing potent anti-inflammatory, analgesic, and antipyretic actions. Unlike non-selective NSAIDs, its relative selectivity for COX-2 over COX-1 is hypothesized to reduce the incidence of gastrointestinal side effects, although this advantage is offset by its notable hepatotoxic potential. Its mechanism also involves other anti-inflammatory effects, such as inhibition of neutrophil activation and the release of proteases.